"The key risk from here, is whether SP3's management will be able to generate a satisfactory return on the capital that is raised. So basically, it comes down to execution risk. "
We meet again!
I've been using this liquidity event to establish a position in this company.
The way I figure is that, at a mere $6m-odd market value [*], not much has to go right for the company to be worth a great deal more than it currently is.
My simple investment thesis goes something like this:
Instead of making an explicit forecast for earnings (which would have very little value because it is little more than a crap shoot at this stage), what I've done is I've reverse-engineered the problem to solve for the level of Revenue that would need to be reached in order to justify the current market value for the business.
So, a case of starting from the bottom of the P&L and working backwards, all the way up to the top line.
I'd be happy to pay 10x P/E for the company, which means it would need to be generating NPAT of around $0.6m
Which works out to Pre-Tax Profit of $0.8m; same as EBIT given there is negligible interest expense.
Depreciation charge runs at around $0.4m pa, so EBITDA is $1.2m
Its a business with a $5m fixed cost base, and it generates 60%-63% GP Margins
So, $1.2m in EBITDA and $5m of fixed costs, meaning Gross Profit of $6.2m.
Grossing-up $6.2m for 60% GP Margin yields required Revenue of around $10.3m
This compares to the current Revenue level of around $5m which is double what it was in FY2018.
For context, SP3's Revenue trend over recent years has been as follows:
FY2016: $0.9m
FY2017: $1.3m
FY2018: $2.5m
FY2019: $4.8m
FY2020: $4.8m (Covid-impacted JH, DH was 19% higher than pcp)
Based on that trend, the large market opportunity that exists, and the differentiated offering in the form of the STA6 platform, I have no doubt that Revenue in excess of $10m is easily attainable.
In fact, it would not surprise me in the least if Sales of $20m were not reported some time over the next few years.
[*] It really has no place being a publicly-listed company, and I suspect that if the execution is poor, those $6m in Revenues $3m in Gross Profit and $2.0m in Net Current Assets will be worth more to someone else!
.
- Forums
- ASX - By Stock
- SP3
- Ann: Investor Presentation
SP3
spectur limited
Add to My Watchlist
0.00%
!
1.3¢

Ann: Investor Presentation, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.005M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 435321 | 1.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 450000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 435321 | 0.012 |
5 | 1458551 | 0.011 |
4 | 3250000 | 0.010 |
2 | 350000 | 0.009 |
1 | 150000 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 450000 | 1 |
0.016 | 3000 | 1 |
0.018 | 120000 | 1 |
0.019 | 347549 | 1 |
0.020 | 40000 | 1 |
Last trade - 16.21pm 02/07/2025 (20 minute delay) ? |
Featured News
SP3 (ASX) Chart |
Day chart unavailable
The Watchlist
RAC
RACE ONCOLOGY LTD
Dr Pete Smith, Executive Chairman
Dr Pete Smith
Executive Chairman
SPONSORED BY The Market Online